BIOCON - Biocon Ltd. Share Price

Biocon Limited's management provided a positive outlook during the Q3 FY26 earnings call, emphasizing the strategic transformation following the acquisition of Viatris' biosimilars business. This transaction valued Biocon Biologics at USD 5.5 billion and is expected to strengthen growth, operational synergies, and long-term value. Key highlights from management include:

1. Market Positioning: Biocon is positioned at the intersection of fast-growing segments, such as interchangeable biosimilar insulins and GLP-1 peptides. Management indicated that the biosimilars pipeline also includes new oncology and immunology products.

2. Financial Performance: In Q3 FY26, operating revenue reached INR 4,173 crores, reflecting a 9% year-on-year growth. The core EBITDA was INR 1,221 crores with a margin of 29%. Reported net profit for the quarter was INR 144 crores, and for the first nine months of FY26, operating revenues grew by 14% and EBITDA by 24%.

3. Biosimilar Growth: The biosimilars division reported revenues of INR 2,497 crores, a 9% year-on-year increase, with an EBITDA of INR 700 crores (up 44% YoY). Management highlighted strong market performance in North America, particularly for products like Yesintek® (biosimilar ustekinumab).

4. Earnings Upgrades: S&P upgraded Biocon Biologics' rating to BB+ with a stable outlook, while Fitch revised its outlook to positive, indicating sustained earnings momentum and improved financials.

5. Cost Management: Management highlighted projected annual savings of approximately INR 300 crores in interest costs from FY27 due to debt reduction efforts, which included raising nearly $1 billion and retiring structured debt.

6. Forward-Looking Statements: Expectations for product launches and growth in the biosimilars and generics market were discussed, indicating management's confidence in future performance amidst a recovering economic landscape.

Biocon remains focused on integrating its operations, enhancing cash flow, and setting the stage for sustainable growth in the coming years.

1. Question: "First question on the biosimilar business, the upgrade of production and quality that you have mentioned, is it fair to assume that this is largely done and behind us? What led to this need for this upgradation of production?"
Answer: Yes, we're nearing completion of our upgrades. The need stemmed from the substantial demand for our products and upcoming launches across various markets. This was a planned operation to enhance our scalability. We believe this positions us for continued growth while maintaining high margins, which exceeded our guidance.

2. Question: "How should we think about growth from here, given we have a bunch of these launches?"
Answer: While I won't provide specific guidance, we've seen strong growth historically. With recent launches and increasing demand, we anticipate growth in the biosimilar business and a potential improvement in margins. The trajectory looks promising as our product pipeline matures.

3. Question: "Can you help us through what the capex would look like for the consolidated entity in fiscal '26 and '27?"
Answer: Our capex is moderating, declining from over $275 million to below $225 million. Most of the heavy investment is behind us, focusing now primarily on doubling our insulin capacity, with only maintenance capex thereafter.

4. Question: "Can you help us understand your other operating expense during the quarter?"
Answer: The operating expenses were roughly INR 1,178 crores, largely fixed in nature. Growth in this line will be lower than revenue growth henceforth, as much of the base spending is already established.

5. Question: "What is your rationale behind acquiring the full global rights for Hulio (adalimumab)?"
Answer: Hulio has been a successful franchise, generating over $200 million annually. Acquiring full rights allows us to have greater control and to fully integrate and expand our offerings in the onco-immunology segment.

6. Question: "What are the drivers for revenue growth in the biologics business?"
Answer: We've maintained year-on-year growth, driven by our diverse product launches and increasing demand. New products are gaining traction, particularly Yesintek in the U.S., which is expected to boost revenue in the coming quarters.

7. Question: "Can you provide an update on the GLP-1s and semaglutide in Canada?"
Answer: We've filed for GLP-1 approvals in several markets, including Canada. The regulatory process is complex, with no approvals yet; however, we're confident that our comprehensive development capabilities will see successful outcomes in the future.

8. Question: "Will the insulin demand remain strong given market trends?"
Answer: Demand for insulin remains robust. We're well-positioned with significant manufacturing capabilities and expect to grow our market share, especially as we double our drug product capacity in the upcoming fiscal year.

9. Question: "Could you clarify the EBITDA of INR 700 crores in the biosimilars business?"
Answer: Yes, this figure is clean EBITDA, with no exceptional gains included. We've focused on prioritizing high-margin markets, which contributed to improved margins despite the overall revenue decline in this period.

10. Question: "Can you share market share information for existing vs. new products?"
Answer: While specific quarter-by-quarter breakdowns are difficult, existing products continue to hold strong market shares, with new launches expected to ramp up and contribute significantly to our overall growth as we move into fiscal '27.